Get the Stockscreener App
2.37
3.27%
-0.08
After Hours:
2.32
-0.05
-2.11%
Protalix BioTherapeutics Inc. stock is traded at $2.37, with a volume of 628.01K.
It is down -3.27% in the last 24 hours and up +30.94% over the past month.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
See More
Previous Close:
$2.45
Open:
$2.39
24h Volume:
628.01K
Relative Volume:
0.91
Market Cap:
$188.97M
Revenue:
$63.63M
Net Income/Loss:
$10.62M
P/E Ratio:
47.40
EPS:
0.05
Net Cash Flow:
$-8.64M
1W Performance:
-5.20%
1M Performance:
+30.94%
6M Performance:
-9.54%
1Y Performance:
+123.58%
1-Day Range:
$2.31
$2.41
1-Week Range:
$2.31
$2.605
52-Week Range:
$1.01
$3.10
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Name
Protalix BioTherapeutics Inc.
Sector
Industry
Phone
972 4 988 9488
Address
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.37 | 195.34M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-17-17 | Reiterated | Rodman & Renshaw | Buy |
| Apr-04-16 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-15 | Upgrade | Jefferies | Hold → Buy |
| Nov-12-14 | Reiterated | R. F. Lafferty | Buy |
| Jan-24-14 | Initiated | R. F. Lafferty | Buy |
| May-02-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-02-12 | Reiterated | Oppenheimer | Outperform |
| Apr-30-12 | Downgrade | Auriga | Buy → Hold |
| Oct-13-11 | Initiated | Morgan Joseph | Hold |
| Mar-17-11 | Downgrade | WBB Securities | Strong Buy → Buy |
| Nov-09-10 | Reiterated | Oppenheimer | Outperform |
| Oct-14-10 | Reiterated | UBS | Buy |
| Dec-02-09 | Reiterated | Hapoalim | Outperform |
| Sep-22-09 | Initiated | Canaccord Adams | Buy |
| Sep-02-09 | Initiated | Hapoalim | Outperform |
| Dec-01-08 | Reiterated | Oppenheimer | Outperform |
| Mar-11-08 | Initiated | UBS | Buy |
| Nov-20-07 | Initiated | CIBC Wrld Mkts | Sector Outperform |
View All
Protalix BioTherapeutics Inc. Stock (PLX) Latest News
Will Protalix BioTherapeutics Inc. stock benefit from AI adoptionGold Moves & Fast Exit Strategy with Risk Control - newser.com
Is Protalix BioTherapeutics Inc. (DE) stock undervalued after correction2025 Trading Volume Trends & Precise Trade Entry Recommendations - newser.com
How to use Fibonacci retracement on Protalix BioTherapeutics Inc.July 2025 PreEarnings & AI Enhanced Trade Execution Alerts - newser.com
How Protalix BioTherapeutics Inc. stock performs in weak economyRate Cut & Weekly Chart Analysis and Trade Guides - newser.com
Why Protalix BioTherapeutics Inc. stock could benefit from AI revolutionGap Up & Real-Time Buy Signal Alerts - newser.com
Detecting price anomalies in Protalix BioTherapeutics Inc. with AIEarnings Summary Report & Free Safe Capital Growth Stock Tips - newser.com
Relative strength of Protalix BioTherapeutics Inc. in sector analysisJuly 2025 Market Mood & Risk Controlled Daily Trade Plans - newser.com
Published on: 2025-10-13 09:33:20 - newser.com
Is Protalix BioTherapeutics Inc. stock positioned for long term growthJuly 2025 Levels & Weekly High Return Opportunities - newser.com
Will breakout in Protalix BioTherapeutics Inc. lead to full recoveryWeekly Earnings Recap & Real-Time Chart Breakout Alerts - newser.com
Earnings visualization tools for Protalix BioTherapeutics Inc.Earnings Growth Report & Expert Verified Movement Alerts - newser.com
Can trapped investors hope for a rebound in Protalix BioTherapeutics Inc.2025 Price Targets & Safe Entry Momentum Stock Tips - newser.com
Can Protalix BioTherapeutics Inc. hit a new high this monthTrade Performance Summary & Smart Swing Trading Techniques - newser.com
Visual analytics tools that track Protalix BioTherapeutics Inc. performanceChart Signals & Capital Protection Trade Alerts - newser.com
Why Protalix BioTherapeutics Inc. (DE) stock appears on watchlistsJuly 2025 Trade Ideas & Risk Adjusted Buy/Sell Alerts - newser.com
Is Protalix BioTherapeutics Inc. (PBDA) stock considered safe haven2025 Key Lessons & Fast Gain Stock Tips - newser.com
Is this a good reentry point in Protalix BioTherapeutics Inc.July 2025 Retail & Growth Focused Stock Reports - newser.com
What analysts say about Protalix BioTherapeutics Inc stockSwing Trading Ideas & Next-Level Stock Intelligence, Now Free - earlytimes.in
Is it too late to sell Protalix BioTherapeutics Inc.Weekly Investment Report & Fast Moving Trade Plans - newser.com
What the charts say about Protalix BioTherapeutics Inc. todayJuly 2025 Levels & Real-Time Chart Breakout Alerts - newser.com
Why Protalix BioTherapeutics Inc. (PBDA) stock gets analyst attention2025 Big Picture & Long-Term Growth Stock Strategies - newser.com
Statistical indicators supporting Protalix BioTherapeutics Inc.’s strengthEarnings Risk Summary & Free High Return Stock Watch Alerts - newser.com
Developing predictive dashboards with Protalix BioTherapeutics Inc. dataJuly 2025 Decliners & Long-Term Growth Plans - newser.com
Published on: 2025-10-02 23:31:20 - newser.com
Published on: 2025-10-02 21:05:30 - newser.com
Published on: 2025-10-01 07:13:09 - newser.com
Protalix BioTherapeutics Inc. Stock (PLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):